Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting

Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors

Iambic’s Rapid Path to the Clinic Enabled by Its AI-Driven Drug Discovery Platform, Built in Collaboration with NVIDIA

Iambic says new AI model bests AlphaFold as protein models rocket ahead

Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers

Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery

San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations (ESMO 2025)

IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

Enchant v2: Pushing the Boundaries of Predictive Drug Discovery

A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)

NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

Enchant whitepaper: Breaking the data wall between lab and clinic

Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers

JPM Healthcare Conference 2026 Company Presentation

Promise & Reality: Decoding AI’s Impact On Drug Development

From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery

Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development

Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance

Predictive Drug Discovery with Enchant v2

Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25

Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum